Eiger BioPharmaceuticals has announced that it will not seek emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for peginterferon lambda to treat mild-to-moderate Covid-19 patients.
Alexion, AstraZeneca Rare Disease has signed a deal to buy genomic medicine company LogicBio Therapeutics.
AeroRx Therapeutics has collaborated with HCmed Innovations to develop a long-acting beta-agonist (LABA) / long-acting muscarinic antagonist (LAMA) combination solution to treat chronic obstructive pulmonary disease (COPD).
Vanda Pharmaceuticals signed a research and development collaboration agreement with OliPass to jointly develop antisense oligonucleotide (ASO) therapeutics.
NETRIS Pharma, Orano and Centre Léon Bérard (CLB) have entered into a scientific collaboration agreement for the development of new antibody radio-conjugates to treat cancer.
The US Food and Drug Administration (FDA) has accepted for priority review Seagen’s supplemental New Drug Application (sNDA) seeking accelerated approval for its medicine tukysa (tucatinib) along with trastuzumab to treat colorectal cancer.
NeuroBo Pharmaceuticals has signed a conditional exclusive license agreement with Dong-A ST for the development and commercialisation of the latter’s cardio-metabolic therapies, DA-1241 and DA-1726.
Coave Therapeutics and the Institute of Neurodegenerative Diseases (IMN) of Bordeaux have entered into collaboration for developing gene therapy programmes that target protein degradation in neurodegenerative disorders.
Novome Biotechnologies has raised $43.5m in a Series B financing round to advance its therapeutically engineered microbes’ pipeline.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease in new-borns and infants through immunisation of women during pregnancy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.